Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies

Hepatology

Volumn 49, Issue 2, 2009, Pages 453-459

  Cho, Yun Ku ^a   Kim, Jae Kyun ^a   Kim, Mi Young ^a   Rhim, Hyunchul ^b   Han, Joon Koo ^c  

^a Seoul Veterans Hospital   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL;

CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; GENETIC HETEROGENEITY; HUMAN; INTERMETHOD COMPARISON; LIVER CELL CARCINOMA; META ANALYSIS; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL; REVIEW; SKIN ABSORPTION; SYSTEMATIC REVIEW; TUMOR GROWTH; CATHETER ABLATION; EUROPE; LIVER TUMOR; METHODOLOGY; MORTALITY; PATIENT SELECTION; SAMPLE SIZE; SURVIVAL; UNITED STATES;

CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; EUROPE; HUMANS; LIVER NEOPLASMS; META-ANALYSIS AS TOPIC; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SAMPLE SIZE; SURVIVAL ANALYSIS; UNITED STATES;

EID: 61949290827     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22648     Document Type: Review

References (42)

1. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Eng J Med 1999;340:745-750.
2. Taylor-Robinson SD, Foster GR, Arora S, Hargreaves S, Thomas HC. Increase in primary liver cancer in the UK, 1979-94. Lancet 1997;350: 1142-1143.
3. Okuda K, Okuda H. Primary liver cell carcinoma. In: McIntyre N, Benhamou JP, Bircher J, Rizzetto M, Rodes J, eds. Oxford Textbook of Clinical Hepatology. Volume 2. Oxford, England: Oxford University Press, 1991:1019-1052.
4. Bruix J, Sherman M. Management of hepatocellular carcinoma. HEPATOLOGY 2005;42:1208-1256.
5. Ryder SD. British Society of Gastroenterology. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut 2003; 52(Suppl 3):S1-S8.
6. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362:1907-1917.
7. Livraghi T, Giorgio A, Martin G, Salmi A, de Sio I, Bolondi L, et al. Hepatocellular carcinoma and cirrhosis in 746 patients: Long-term results of percutaneous ethanol injection. Radiology 1995;197:101-108.
8. Livraghi T. Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in cirrhosis. Hepatogastroenterology 2001;48:20-24.
9. Shiina S, Tagawa K, Unuma T, Takanashi R, Yoshiura K, Komatsu Y, et al. Percutaneous ethanol injection therapy for hepatocellular carcinoma: A histopathologic study. Cancer 1991;68:1524-1530.
10. Ohnishi K, Yoshioka H, Ito S, Fujiwara K. Prospective randomized controlled trial comparing percutaneous acetic acid injection and percutaneous ethanol injection for small hepatocellular carcinoma. HEPATOLOGY 1998;27:67-72.
11. Huo TI, Huang YH, Wu JC, Lee PC, Chang FY, Lee SD. Comparison of percutaneous acetic acid injection and percutaneous ethanol injection for hepatocellular carcinoma in cirrhotic patients: A prospective study. Scand J Gastroenterol 2003;38:770-778.
12. Shibata T, Iimuro Y, Yamatomo Y, Maetani Y, Ametani F, Itoh K, et al. Small hepatocellular carcinoma: Comparison of percutaneous radiofrequency thermal ablation versus percutaneous microwave coagulation therapy. Radiology 2002;223:331-337.
13. Liang P, Dong B, Yu X, Yu D, Wang Y, Feng L, et al. Prognostic factors for survival in patients with hepatocellular carcinoma after percutaneous microwave ablation. Radiology 2005;235:299-307.
14. Izzo F. Other thermal ablation techniques: Microwave and interstitial laser ablation of liver tumors. Ann Surg Oncol 2003;10:491-497.
15. Vogl TJ, Müller PK, Hammerstingl R, Weinhold N, Mack MG, Philipp C, et al. Malignant liver tumors treated with MR imaging-guided laser-induced thermotherapy: Technique and prospective results. Radiology 1995;196:257-265.
16. Adam R, Akpinar E, Johann M, Kunstlinger F, Majno P, Bismuth H, et al. Place of cryosurgery in the treatment of malignant liver tumors. Ann Surg 1997;225:39-50.
17. Jungraithmayr W, Burger D, Olschewski M, Eggstein S. Cryoablation of malignant liver tumors: Results of a single center study. Hepatobiliary Pancreat Dis Int 2005;4:554-560.
18. Rossi S, Di Stasi M, Buscarini E, Cavanna L, Quaretti P, Squassante E, et al. Percutaneous radiofrequency interstitial thermal ablation in the treatment of small hepatocellular carcinoma. Cancer J Sci Am 1995;1:73-81.
19. Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Solbiati L, Gazelle GS. Small hepatocellular carcinoma: Treatment with radiofrequency ablation versus ethanol injection. Radiology 1999;210:655-661.
20. Lencioni RA, Allgaier HP, Cioni D, Olschewski M, Deibert P, Crocetti L, et al. Small hepatocellular carcinoma in cirrhosis: Randomized comparison of radiofrequency thermal ablation versus percutaneous ethanol injection. Radiology 2003;228:235-240.
21. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm. Gastroenterology 2004;127:1714-1723.
22. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut 2005;54:1151-1156.
23. Shiina S, Teratani T, Obi S, Sato S, Tateishi R, Fujishima T, et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005;129:122-130.
24. Brunello F, Veltri A, Carucci P, Pagano E, Ciccone G, Moretto P, et al. Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: A randomized controlled trial. Scand J Gastroenterol 2008;43: 727-735.
25. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al; EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35: 421-430.
26. Sutherland LM, Williams J, Padbury R, Gotley D, Stokes B, Maddern G. Radiofrequency ablation of liver tumors: A systematic review. Arch Surg 2006;141:181-190.
27. Lopez PM, Villanueva A, Llovet JM. Systematic review: Evidence-based management of hepatocellular carcinoma - an updated analysis of randomized controlled trials. Aliment Pharmacol Ther 2006;23:1535-1547.
28. Jahad A, Moore A, Carroll D, Jenikson C, Reynols J, Gavaghan D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Controlled Clin Trials 1996;17:1-12.
29. Pogue J, Yusuf S. Cumulating evidence from randomized trials: Utilizing sequential monitoring boundaries for cumulative meta-analysis. Controlled Clin Trials 1997;18:580-593.
30. Pogue J, Yusuf S. Overcoming the limitations of current meta-analysis of randomized trials. Lancet 1998;351:47-52.
31. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. HEPATOLOGY 2003;37:429-441.
32. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clin Trials 1986;7:177-188.
33. Levine RS, Briggs NC, Kilbourne BS, King WD, Fry-Johnson Y, Baltrus PT, et al. Black white mortality from HIV in the United States before and after introduction of highly active antiretroviral therapy in 1996. Am J Public Health 2007;97:1884-1892.
34. Buchan IE. StatsDirect: Statistical software for medical research in the 21st century. BMJ 2000;321:1536.
35. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF, et al, for the QUORUM Group. Improving the quality of reports of meta-analysis of randomized controlled trials: The QUORUM statement. Lancet 1999; 354:1896-1900.
36. Cochrane Collaboration guidelines for reporting systematic reviews. Available at: Http://www.cochrane.dk/cochrane/handbook. Accessed August 2008.
37. Goldberg SN. Radiofrequency tumor ablation: Principles and techniques. Eur J Ultrasound 2001;13:129-147.
38. Okusaka T, Okada S, Ueno H, Ikeda M, Shimada K, Yamamoto J, et al. Satellite lesions in patients with small hepatocellular carcinoma with reference to clinicopathologic features. Cancer 2002;95:1931-1937.
39. Cha CH, Lee FT, Gurney JM, Markhardt BK, Warner TF, Kelca F, et al. CT versus sonography for monitoring radiofrequency ablation in a porcine liver. AJR Am J Roentgenol 2000;175:705-711.
40. Okada S. Local ablation therapy for hepatocellular carcinoma. Semin Liver Dis 1999;19:323-328.
41. Horigome H, Nomura T, Saso K, Itoh M. Standards for selecting percutaneous ethanol injection therapy or percutaneous microwave coagulation therapy for solitary small hepatocellular carcinoma: consideration of local recurrence. Am J Gastroenterol 1999;94:1914-1917.
42. Moher D, Pham B, Klassen TP, Schulz KF, Berlin JA, Jada AR, et al. What contributions do languages other than English make on the results of meta-analyses? J Clin Epidemiol 2000;53:964-972.